To date, the collective research on transcription factors has been elusive to drug discovery. Flare Therapeutics, an early-stage biotech, has now reached a moment of light - with the prospect of forever changing the trajectory of how we treat disease. We are trailblazing the path to transcription factors by intervening at a previously hidden region we have identified as the 'switch site.' Join us and help illuminate the path to the possible.
In this role you will…
- Develop and validate assays with a high degree of independence to drive drug discovery campaigns
- Collaborate with chemistry and biochemistry colleagues to understand the mechanism of action of small molecule modulators of transcription factors to improve compound efficacy for H2L and LO advancement
- Support cell and molecular biology activities across Flare’s early pipeline projects
- Present data and research plans to the teams to inform data-driven decisions
About you…
- You have a BS or MS in molecular or cellular biology
- You have at least 5 years of experience in biotech/pharma post-degree (required)
- You have experience with cell assay development, drug discovery screening and mechanistic studies
- You are experienced in cell engineering (shRNA, CRISPR knockin/knockout, generation of stable lines, viral transduction, etc.)
- You have worked in oncology and/or transcriptional regulation
- You are passionate about science, driven to make a real difference for patients, and maybe you have even been caught reading scientific journals for fun
- You are a proactive individual able to prioritize and balance multiple tasks, meet multiple deadlines, and thrive in a dynamically changing and fast-paced environment
- You thrive on feedback and love collaborating as part of a team
- You have strong communication skills, both written and verbal, including presenting data to internal company meetings
Top Skills
What We Do
Our team ‘brings it’ every day for one mission: to conquer transcription factors and create cutting-edge medicines for patients.
Flare is lighting up a new therapeutic space with an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of our scientific founders, Flare’s team is leveraging the power of ‘switch sites’ as druggable regions that hold the control for predictable and profound changes in DNA transcription, and therefore, gene expression. Our drug discovery to target ‘switch sites’ has rapidly advanced, resulting in our pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology.
